GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells

$281,059
Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2015 · CA

Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells

$281,059
Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2016 · CA

The CXCR4-SDF-1 Axis in Metastatic Rhabdomyosarcoma

$281,043
University Of Louisville · R01 · FY2005 · CA

Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer

$280,975
Brett Stewart Carver · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA

Reversing/Blocking T cell suppression by extracellular vesicles as cancer therapy

$280,928
Maulasri Bhatta · Immune Modulatory Therapies, Llc · R43 · FY2018 · CA

Role of cPLA2 in Lung Cancer: Microenvironment vs Tumor Cells

$280,917
Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2010 · CA

OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE

$280,910
Cliona M Rooney · Baylor College Of Medicine · P01 · FY2010 · CA

Novel Methods for Detecting Cell Interactions in the Tumor Microenvironment

$280,899
John S Condeelis · Albert Einstein College Of Medicine · U54 · FY2007 · CA

Retinoid Nutritional Status and Immune Function

$280,893
A Catharine Ross · Pennsylvania State University, The · R01 · FY2010 · DK

Mechanisms of Macrophage Activation

$280,880
Thomas Alan Hamilton · Cleveland Clinic Lerner Com-Cwru · R01 · FY2007 · CA

Role of an Epithelial Ets Factor in Breast Cancer

$280,880
Medical University Of South Carolina · R01 · FY2004 · CA

Mechanisms of Macrophage Activation

$280,880
Thomas Alan Hamilton · Cleveland Clinic Lerner Com-Cwru · R01 · FY2006 · CA

DEVELOPMENTAL FUNDS

$280,873
Paul A Bunn · University Of Colorado Denver · P30 · FY2013 · CA

Role of Stat3 in Tumor Immune Evasion and Immune Suppression

$280,866
Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2014 · CA

Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)

$280,834
Robert Loberg · University Of Michigan At Ann Arbor · P50 · FY2010 · CA

Project 1: Modeling the Interface between Non-invasive Imaging and Drug Distribution

$280,807
Kristin R Swanson · Massachusetts Institute Of Technology · U54 · FY2017 · CA

Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma

$280,797
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · P50 · FY2017 · CA

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple Myeloma

$280,796
Yi Lin · Mayo Clinic Arizona · P50 · FY2025 · CA

Design, Synthesis, and Evaluation of ant-Glioblastoma Agents

$280,786
Paul E Floreancig · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · GM

Project 4. Targeting genomic instability and evolution in myeloma

$280,769
Nikhil C. Munshi · Dana-Farber Cancer Inst · P01 · FY2019 · CA

Project 4. Targeting genomic instability and evolution in myeloma

$280,767
Nikhil C. Munshi · Dana-Farber Cancer Inst · P01 · FY2020 · CA

Project 4. Targeting genomic instability and evolution in myeloma

$280,767
Nikhil C. Munshi · Dana-Farber Cancer Inst · P01 · FY2018 · CA

Project 4. Targeting genomic instability and evolution in myeloma

$280,767
Nikhil C. Munshi · Dana-Farber Cancer Inst · P01 · FY2021 · CA

Immunotherapy of Advanced Non-small Cell Lung Cancer

$280,764
Lieping Chen · Yale University · P50 · FY2019 · CA

Microbial Dysbiosis in Pancreatic Cancer Initiation and Progression

$280,670
Donnele Daley · University Of Michigan At Ann Arbor · K08 · FY2023 · CA